Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 26, 2024 08:00 ET | Source: Actuate Therapeutics

Actuate Therapeutics to be Added to Russell 2000® Index

CHICAGO and FORT WORTH, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on...
November 12, 2024 08:00 ET | Source: Actuate Therapeutics

Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma

Ewing Sarcoma is a Highly Metastatic Form of Sarcoma and the Second Most Prevalent Primary Malignant Tumor in Children and AdolescentsOngoing Enrollment in Phase 1/2 Trial of Elraglusib in...
October 29, 2024 18:39 ET | Source: Actuate Therapeutics

Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development

Companies will discuss how Lantern’s AI platform is being leveraged for the identification and development of enrichment biomarkers for Actuate’s lead investigational drug product, elraglusib ...
September 23, 2024 08:00 ET | Source: Actuate Therapeutics

Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor

New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the treatment of NeuroblastomaStudy Illustrates Potential to Activate the Immune System Even in...
September 16, 2024 08:00 ET | Source: Actuate Therapeutics

Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research

Preclinical Study Highlight the Potential of Elraglusib in Overcoming FOLFIRINOX-induced Chemoresistance Through Downregulation of Epithelial to Mesenchymal Transition (EMT)Initial Data Demonstrates...
September 11, 2024 08:00 ET | Source: Actuate Therapeutics

Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas

Elraglusib is a Class-Leading GSK-3β Inhibitor with a Novel, Multimodal Mechanism of Action in Multiple Refractory Cancer TrialsOrphan Drug Designation in Soft Tissue Sarcomas Expands Company’s...
September 09, 2024 08:00 ET | Source: Actuate Therapeutics

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

Elraglusib Demonstrated Anti-Tumor Activity with Two Ongoing Durable Complete Responses and ~62% Disease Control Rate in First 8 Patients with Relapsed/Refractory Ewing and Ewing-related...
September 05, 2024 09:10 ET | Source: Actuate Therapeutics

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

CHICAGO and FORT WORTH, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on...
August 20, 2024 09:00 ET | Source: Actuate Therapeutics

Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024

CHICAGO and FORT WORTH, Texas, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on...
August 14, 2024 16:05 ET | Source: Actuate Therapeutics

Actuate Therapeutics Announces Closing of Initial Public Offering

CHICAGO and FORT WORTH, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing therapies...